Abbott

Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation - Recurrent irregular heartbeat-also known as

Abbott Receives FDA Approval for iOS-Compatible App Allowing People Living With Chronic Pain and Movement Disorders to Personalize Therapy Via

- Worldwide sales of $7.3 billion in the second quarter, including $615 million of COVID-19 diagnostic testing-related sales - Growth

Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences ABBOTT PARK, Ill., July 13, 2020 /PRNewswire/ — Abbott (NYSE:

Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring - Next-generation Gallant™ implantable

Abbott and Tandem Diabetes Care Advance Development of Integrated Technologies for Future Automated Insulin Delivery Systems - Companies partner to

New Research Finds Abbott’s Optical Coherence Tomography Imaging Changed Treatment Decisions in 88% of Artery Blockages — Using optical coherence

New Late-Breaking Data Highlight Impact of Abbott’s Minimally Invasive Structural Heart Therapies - New data reinforce Abbott’s leadership in minimally

ABBOTT PARK, Ill., June 23, 2020 /PRNewswire/ — Abbott (NYSE: ABT) will announce its second-quarter 2020 financial results on Thursday, July

New Data Show Use of Abbott’s FreeStyle® Libre System Reduces All-Cause, Diabetic Ketoacidosis-Related Hospitalization Rates and Acute Diabetes Events -

Abbott’s FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and

New Late-Breaking Data Show Use of Abbott’s FreeStyle® Libre System Significantly Reduces HbA1C Levels in People with Type 2 Diabetes

ABBOTT PARK, Ill., June 12, 2020 /PRNewswire/ — The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend

Abbott Releases Interim Clinical Study Data on ID NOW COVID-19 Rapid Test Showing Strong Agreement to Lab-Based Molecular PCR Tests

Abbott Announces Contract to Supply Millions of IgG Lab-Based Antibody Tests to the UK Government - Abbott’s antibody test to

ABBOTT PARK, Ill., May 14, 2020 /PRNewswire/ — (NYSE: ABT) — Abbott’s ID NOW™ is the fastest molecular point-of-care rapid

Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity™ m System - Alinity m is Abbott’s

Abbott MediaRoom https://abbott.mediaroom.com/ Abbott Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity™ i System https://abbott.mediaroom.com/2020-05-11-Abbott-Receives-FDA-Emergency-Use-Authorization-for-COVID-19-Antibody-Blood-Test-on-Alinity-TM-i-System -

Abbott Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity™ i System - Data shows reliable results

Research from University of Washington Demonstrates High Performance of Abbott’s SARS-CoV-2 Antibody Blood Test - Researchers found the test to

“The in-hospital challenges presented by the COVID-19 pandemic have forced frontline workers to think creatively about how to safeguard against

- Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19) ABBOTT PARK, Ill., April 16, 2020 /PRNewswire/ — Abbott (NYSE: ABT)

Abbott Launches Third COVID-19 Test, a Laboratory-Based Antibody Blood Test That Will Ship in the U.S. Starting Tomorrow - This

ABBOTT PARK, Ill., April 14, 2020 /PRNewswire/ — Abbott (NYSE: ABT) announced today that due to the public health impact of the

Abbott’s TriClip™ Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair - CE